Quant Healthcare Fund
Pharma and Healthcare · Direct plan · Growth
₹19.27
-₹0.05 (-0.24%) today
NAV on 20 Nov 2026
Returns
Up to a year
| Period | This fund | NIFTY Healthcare | Rank |
|---|---|---|---|
| 1 month | +7.41% | +12.34% | 19/19 |
| 3 months | +0.97% | +6.15% | 18/18 |
| 6 months | +12.45% | +10.59% | 11/18 |
| This year | +23.61% | +19.97% | 9/18 |
| 1 year | +20.24% | +18.04% | 10/17 |
Longer term
| This fund | NIFTY Healthcare | NIFTY Healthcare | Category | ||||
|---|---|---|---|---|---|---|---|
| Total | A year | Total | A year | A year | Rank | ||
| 2 years | +19.65% | +9.4% | +13.0% | – | |||
| 3 years | +72.38% | +19.9% | +20.9% | 10/12 | |||
| 5 years | – | – | +15.6% | – | |||
| 7 years | – | – | +21.2% | – | |||
| 10 years | – | – | +12.3% | – | |||
| Since inception | +92.68% | +21.7% | +22.3% | – | |||
₹1 lakh invested 3 years ago is ₹1.72 lakh today.
From the plan's own NAV, to 20 Nov 2026. Rank 1 is best. Past returns are no guide to the future.
RiskWorst fall -25.2% · volatility 18.0% a year
Volatility, 3 years
18.0%
NIFTY Healthcare 16.4%
Worst fall
-25.2%
Mar 2025, back by Jul 2026
Worst calendar year
-3.6%
2025
Up months
61%
last 3 years
Against other pharma and healthcare funds, last 3 years (worst fall: 5 years)
Volatility
! 18.0%
Swings more than peers · average 16.0%
13 of 13
Sharpe ratio
! 0.72
Less return for the risk · average 0.99
12 of 12
Yearly cost
! 1.62%
Dearer than peers · average 1.10%
18 of 18
More measures ›Fewer measures ‹
Sharpe ratio, 3 years
0.72
Return above the CRISIL Overnight Index per unit of volatility
Sortino ratio, 3 years
1.19
The same, counting only falls
Alpha vs NIFTY Healthcare
+0.15%
Yearly return beyond what its beta explains
Beta vs NIFTY Healthcare
0.92
Moves this much when the index moves 1%
Share of the index's rises
77%
In months the index rose
Share of the index's falls
57%
In months the index fell; lower is better
Over the last 3 years, from the fund's NAVs against the NIFTY Healthcare.
Where it ranksAgainst 19 pharma and healthcare funds
Category rank, year by year
In the top half of pharma and healthcare funds in 1 of 3 calendar years.
Top quarter in 0, bottom quarter in 2.
9/18
Rank in 2026 YTD
'172017
N/A
'182018
N/A
'192019
N/A
'202020
N/A
'212021
N/A
'222022
N/A
'232023
N/A
'242024
Q4
13/13
'252025
Q4
13/16
'262026YTD
Q2
9/18
Each year ranks the pharma and healthcare funds by that year's return from their own Direct Growth NAV; Q1 is the top quarter. 2026 is year to date. The peer group is today's funds, so funds that closed or merged in earlier years are not counted. Past performance does not indicate future returns.
Where it ranks
among 19 pharma and healthcare funds, Direct plans1 year
10 of 17
Third quarter
3 years
10 of 12
Bottom quarter
Lowest cost
18 of 18
Bottom quarter
| Best over 3 years | 3 years | A year | Cost | Size |
|---|---|---|---|---|
| 1HDFC Pharma and Healthcare Fund | +123.0% | +30.6% | 1.04% | ₹3,666 Cr |
| 2SBI Healthcare Opportunities Fund | +94.4% | +24.8% | 1.00% | ₹6,067 Cr |
| 3Mirae Asset Healthcare Fund | +90.9% | +24.0% | 0.61% | ₹3,562 Cr |
| 4UTI Healthcare Fund | +87.3% | +23.3% | 1.34% | ₹1,433 Cr |
| 5LIC MF Healthcare Fund | +80.9% | +21.9% | 1.38% | ₹96.54 Cr |
| 10Quant Healthcare Fund this fund | +72.4% | +19.9% | 1.62% | ₹417 Cr |
Every fund in the category computed from its own NAV the same way, to 20 Nov 2026. All Pharma and Healthcare funds ›
What stands out
What it holds
24 holdings · as of Aug 2026
- 1Cash, TREPS and repo22.66%
- 2Glaxosmithkline Pharmaceuticals Ltd10.58%
- 3Glenmark Pharmaceuticals Ltd 29/09/20269.83%
- 4Divi's Laboratories Ltd 29/09/20269.46%
- 5Zydus Lifesciences Ltd9.30%
- 6Pfizer Ltd8.83%
- 7Glenmark Life Sciences Ltd8.08%
- 8Torrent Pharmaceuticals Ltd 29/09/20267.87%
- 9Concord Biotech Ltd7.03%
- 10SMS Pharmaceuticals Ltd6.71%
SIP returns of pharma and healthcare funds · All pharma and healthcare funds · Fund screener
About Quant Healthcare Fund Growth Option Direct Plan
Quant Healthcare Fund Growth Option Direct Plan is a Sector Specific - Pharma equity fund from Quant Money Managers Limited, launched on 11 Jul 2023. Its benchmark is the NIFTY Healthcare Index. The expense ratio is 1.62% a year. It manages ₹417 crore. The NAV was ₹19.27 on 20 Nov 2026.
Questions about Quant Healthcare Fund
What is the NAV of Quant Healthcare Fund Direct Growth?
The NAV of Quant Healthcare Fund Direct Growth was ₹19.27 on 20 Nov 2026. Mutual fund NAVs are published once a day, after markets close.
What are the returns of Quant Healthcare Fund Direct Growth?
Quant Healthcare Fund Direct Growth returned 20.2% over 1 year and 19.9% a year over 3 years, to 20 Nov 2026, worked out from its own daily NAV. It returned more than the NIFTY Healthcare Index in 1 of 4 calendar years since 2023.
What is the expense ratio of Quant Healthcare Fund Direct Growth?
1.62% a year. It is taken from the fund's assets every day, so the NAV and every return shown are already after this cost.
Can NRIs in the UAE invest in Quant Healthcare Fund?
NRIs can generally invest once KYC is complete, paying from an NRE or NRO account. Quant Mutual Fund accepts investors living in the US only on conditions and does not accept investors living in Canada, per its own documents checked on 15 Nov 2026. Rules change, so confirm with the fund house.
How are Quant Healthcare Fund gains taxed for NRIs?
India taxes gains on equity funds at 20% on units held 12 months or less, and at 12.5% on gains above ₹1.25 lakh a year on units held longer, plus cess and any surcharge. For NRIs the tax is deducted when units are redeemed. The UAE has no personal income tax, and the India UAE tax treaty may apply, so confirm your position with a tax adviser.
Rolling returns shows every period, not just the latest.
Compare every pharma and healthcare fund on returns, volatility, worst fall and cost.













